Gliclazide and C-reactive protein abnormal - a phase IV clinical study of FDA data

Summary:

C-reactive protein abnormal is reported as a side effect among people who take Gliclazide (gliclazide), especially for people who are female, 50-59 old, also take Enbrel, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have C-reactive protein abnormal when taking Gliclazide. It is created by eHealthMe based on reports of 27,903 people who have side effects when taking Gliclazide from the FDA, and is updated regularly.

What is Gliclazide?

Gliclazide has active ingredients of gliclazide. It is often used in diabetes. eHealthMe is studying from 28,131 Gliclazide users. Check the latest studies of Gliclazide.

What is C-reactive protein abnormal?

C-reactive protein abnormal is found to be associated with 411 drugs and 280 conditions by eHealthMe. Check the latest studies of C-reactive protein abnormal.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

27,903 people reported to have side effects when taking Gliclazide.
Among them, 68 people (0.24%) have C-reactive protein abnormal.

Could Gliclazide cause C-reactive protein abnormal?

Among these 68 people:

What is the gender of people who have C-reactive protein abnormal when taking Gliclazide? *

female: 98.48 %
male: 1.52 %

What is the age of people who have C-reactive protein abnormal when taking Gliclazide? *

What are other drugs people take besides Gliclazide? *

What are other side effects people have besides C-reactive protein abnormal? *

Red Blood Cell Sedimentation Rate Abnormal: 68 people, 100.00%
Pain In Extremity: 67 people, 98.53%
Drug Ineffective: 65 people, 95.59%
Oedema Peripheral (superficial swelling): 51 people, 75.00%
Peripheral Swelling: 51 people, 75.00%
Joint Pain: 50 people, 73.53%
Joint Range Of Motion Decreased (disease of joint movement): 50 people, 73.53%
Lip Dry: 50 people, 73.53%
Liver Disorder (liver diseases): 50 people, 73.53%
Lung Disorder (lung disease): 50 people, 73.53%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 67 people, 98.53%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 13 people, 19.12%
Nephrogenic Anaemia (anaemia due to kidney disease): 1 person, 1.47%
High Blood Cholesterol: 1 person, 1.47%

* Approximation only. Some reports may have incomplete information.

Do you take Gliclazide and have C-reactive protein abnormal?

- Check whether C-reactive protein abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gliclazide:

Gliclazide (28,131 reports)

Browse all side effects of Gliclazide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with C-reactive protein abnormal:

C-reactive protein abnormal (411 drugs)

Browse all the conditions that are associated with C-reactive protein abnormal:

C-reactive protein abnormal (280 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gliclazide (the active ingredients of Gliclazide) and Gliclazide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.